logo

For the Inventor, By the Inventor

Baltimore, MD, United States of America

Brett R Ullman

This inventor holds 3 USPTO granted patents and 3 published patent applications. Top assignees: Johns Hopkins University, Rapafusyn Pharmaceuticals, Inc.. Active years: 2021-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Brett R Ullman. Retrieved from https://idiyas.com/inventor/brett-r-ullman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 3 

% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:

goldMedal3 out of 3,806 
 
Johns Hopkins University
 patents
silverMedal2 out of 2 
 
Rapafusyn Pharmaceuticals, Inc.
 patents
where one patent can have more than one assignee

Years Active: 2021-2026

Loading Chart...
3 patents (USPTO):Explore Patents
1. 12540144 - Rapafucin derivative compounds and methods of use thereof (2026-02-03),
2. 11945827 - Rapafucin derivative compounds and methods of use thereof (2024-04-02),
3. 11066416 - Rapafucin derivative compounds and methods of use thereof (2021-07-20),

Title: Brett R Ullman: Innovator in Macrocyclic Compounds

Introduction

Brett R Ullman is a notable inventor based in Baltimore, MD (US). He has made significant contributions to the field of pharmaceuticals, particularly through his work on macrocyclic compounds. With a total of 3 patents, Ullman is recognized for his innovative approaches to drug development.

Latest Patents

Ullman's latest patents include the development of Rapafucin derivative compounds and methods of use thereof. These patents provide macrocyclic compounds inspired by the immunophilin ligand family of natural products FK506 and rapamycin. The generation of a Rapafucin library of macrocycles that contain FK506 and rapamycin binding domains holds great potential as new leads for developing drugs aimed at treating various diseases.

Career Highlights

Throughout his career, Ullman has worked with prestigious institutions such as Johns Hopkins University and Rapafusyn Pharmaceuticals, Inc. His work has been instrumental in advancing the understanding and application of macrocyclic compounds in medicine.

Collaborations

Ullman has collaborated with notable individuals in his field, including Joseph E Semple and Kana Yamamoto. These partnerships have contributed to the success of his research and innovations.

Conclusion

Brett R Ullman is a distinguished inventor whose work in macrocyclic compounds has the potential to revolutionize drug development. His contributions to the field are significant and continue to inspire future innovations.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…